Mountzios 2009.
| Methods | Randomised Phase II clinical trial | |
| Participants | 153 women with metastatic, persistent or recurrent cervical cancer. performance status 0 to 2 | |
| Interventions | Arm 1: ifosfamide 1.5 g/m2 d1‐3 plus cisplatin 70 mg/m2 d2 q28 Arm 2: ifosfamide 1.5 g/m2 d1‐3 plus cisplatin 70 mg/m2 d2 plus paclitaxel 175 mg/m2 d1 q28 |
|
| Outcomes | Response rates PFS OS Toxicity |
|
| Notes | 4 patients excluded (3 had had previous chemotherapy, 1 previous primary cancer) | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not documented |
| Allocation concealment (selection bias) | Unclear risk | Not documented |
| Blinding (performance bias and detection bias) All outcomes | Unclear risk | Not documented but OS unlikely to be affected by blinding |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing outcome data |
| Selective reporting (reporting bias) | Low risk | Published report included all pre‐specified outcomes |
| Other bias | Low risk | No hint at any other possible biases |